Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

Core Insights - Xencor, Inc. announced initial results from a Phase 1 dose-escalation study of XmAb819, a bispecific antibody targeting ENPP3 and CD3, for treating advanced clear cell renal cell carcinoma (ccRCC) [1] Company Overview - Xencor, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and autoimmune diseases [1] Study Details - The results of the ongoing Phase 1 study were presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics [1]